Similar articles for PMID: 31570451

Year	Number of Results
2007	1
2008	4
2009	4
2010	3
2011	3
2012	2
2013	5
2014	1
2015	4
2016	10
2017	10
2018	15
2019	11
2020	20
2021	17
2022	4
2023	2
2024	0

1

Impact of Extravasated Platelet Activation and Podoplanin-positive Cancer-associated Fibroblasts in Pancreatic Cancer Stroma.

Miyashita T, Tajima H, Gabata R, Okazaki M, Shimbashi H, Ohbatake Y, Okamoto K, Nakanuma S, Sakai S, Makino I, Kinoshita J, Hayashi H, Nakamura K, Takamura H, Ninomiya I, Fushida S, Harmon JW, Ohta T. Miyashita T, et al. Anticancer Res. 2019 Oct;39(10):5565-5572. doi: 10.21873/anticanres.13750. Anticancer Res. 2019. PMID: 31570451

2

Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-paclitaxel Reduces the Number of Cancer-associated Fibroblasts Through Depletion of Pancreatic Stroma.

Miyashita T, Tajima H, Makino I, Okazaki M, Yamaguchi T, Ohbatake Y, Nakanuma S, Hayashi H, Takamura H, Ninomiya I, Fushida S, Kishimoto K, Harmon JW, Ohta T. Miyashita T, et al. Anticancer Res. 2018 Jan;38(1):337-343. doi: 10.21873/anticanres.12227. Anticancer Res. 2018. PMID: 29277792

3

Comparison of Chemotherapy-induced Nausea and Vomiting Between Gemcitabine Plus Nab-paclitaxel Combination Chemotherapy and Gemcitabine Monotherapy in Patients With Advanced Pancreatic Cancer.

Ohata K, Fujii H, Sadaka S, Kato-Hayashi H, Iihara H, Kobayashi R, Uemura S, Iwashita T, Shimizu M, Suzuki A. Ohata K, et al. Anticancer Res. 2021 Jul;41(7):3643-3648. doi: 10.21873/anticanres.15154. Anticancer Res. 2021. PMID: 34230162

4

Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study.

Zong Y, Yuan J, Peng Z, Lu M, Wang X, Shen L, Zhou J. Zong Y, et al. J Cancer Res Clin Oncol. 2021 May;147(5):1529-1536. doi: 10.1007/s00432-020-03442-0. Epub 2020 Nov 15. J Cancer Res Clin Oncol. 2021. PMID: 33191450 Clinical Trial.

5

Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.

Li Y, Sun J, Jiang Z, Zhang L, Liu G. Li Y, et al. J Chemother. 2015 Aug;27(4):227-34. doi: 10.1179/1973947815Y.0000000013. Epub 2015 Mar 20. J Chemother. 2015. PMID: 25790948

6

Efficacy and safety comparison of nabpaclitaxel plus S-1 and gemcitabine plus S-1 as first-line chemotherapy for metastatic pancreatic cancer.

Xu Y, Guo X, Fan Y, Wang D, Wu W, Wu L, Liu T, Xu B, Feng Y, Wang Y, Lou W, Zhou Y. Xu Y, et al. Jpn J Clin Oncol. 2018 Jun 1;48(6):535-541. doi: 10.1093/jjco/hyy063. Jpn J Clin Oncol. 2018. PMID: 29718363

7

Safety and efficacy of MIKE-1 in patients with advanced pancreatic cancer: a study protocol for an open-label phase I/II investigator-initiated clinical trial based on a drug repositioning approach that reprograms the tumour stroma.

Mizutani Y, Iida T, Ohno E, Ishikawa T, Kinoshita F, Kuwatsuka Y, Imai M, Shimizu S, Tsuruta T, Enomoto A, Kawashima H, Fujishiro M. Mizutani Y, et al. BMC Cancer. 2022 Feb 24;22(1):205. doi: 10.1186/s12885-022-09272-2. BMC Cancer. 2022. PMID: 35209871 Free PMC article.

8

Stromal disrupting effects of nab-paclitaxel in pancreatic cancer.

Alvarez R, Musteanu M, Garcia-Garcia E, Lopez-Casas PP, Megias D, Guerra C, Muñoz M, Quijano Y, Cubillo A, Rodriguez-Pascual J, Plaza C, de Vicente E, Prados S, Tabernero S, Barbacid M, Lopez-Rios F, Hidalgo M. Alvarez R, et al. Br J Cancer. 2013 Aug 20;109(4):926-33. doi: 10.1038/bjc.2013.415. Epub 2013 Aug 1. Br J Cancer. 2013. PMID: 23907428 Free PMC article.

9

The impact of body composition on short-term outcomes of neoadjuvant chemotherapy with gemcitabine plus S-1 in patients with resectable pancreatic cancer.

Takeda T, Sasaki T, Mie T, Furukawa T, Yamada Y, Kasuga A, Matsuyama M, Ozaka M, Sasahira N. Takeda T, et al. Jpn J Clin Oncol. 2021 Apr 1;51(4):604-611. doi: 10.1093/jjco/hyaa247. Jpn J Clin Oncol. 2021. PMID: 33479765

10

Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1).

Gao S, Zhu X, Shi X, Cao K, Bian Y, Jiang H, Wang K, Guo S, Zhang H, Jin G. Gao S, et al. Radiat Oncol. 2019 Mar 27;14(1):52. doi: 10.1186/s13014-019-1254-8. Radiat Oncol. 2019. PMID: 30917842 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

102 results

Results by year